tirzepatide osa fda approval The approved Zepbound (tirzepatide) as the first prescription medication for adults with moderate-to-severe obstructive sleep apnea and obesity, providing a new option for people managing… tirzepatide sleep apnea fda approval

Compact, portable, and reliable, it keeps medication at a safe temperature during travel, commutes, or busy days outso you never have to worry about losing effectiveness

doi:10.1371/journal.pone.0008666.[Crossref], [PubMed], [Web of Science ] , [Google Scholar])

Wariss, B.R., Costa, R.M., Pereira, A.C.P.R., Koifman, R.J

In trial 1, the mean change in AHI at week 52 was a reduction of 25.3 events per hour with tirzepatide, compared to a reduction of 5.3 events per hour with placebo, resulting in a treatment difference of -20.0 events per hour (95% CI, 25.8 to 14.2

Improved glycaemic control from GLP-1 therapy may reduce diabetes-related fatigue caused by fluctuating blood glucose levels